0RCQ.L
NICOX SA NICOX ORD SHS
£0.38
-0.26%
2026-05-29
About NICOX SA NICOX ORD SHS
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
Key Fundamentals
EPS (TTM)
£-1.17
ROE
-51.2%
Revenue Growth (YoY)
751.8%
Profit Margin
-14.4%
Debt/Equity
6.71
Price/Book
5.65
Beta
0.53
Market Cap
£11.7M
Avg Volume (10D)
22
Recent Breakout Signals
No recent breakout signals detected for 0RCQ.L.
Recent Price Range (60 Days)
60D High
£0.47
60D Low
£0.37
Avg Volume
6K
Latest Close
£0.38
Get breakout alerts for 0RCQ.L
Sign up for Breakout Scanner to receive daily notifications when 0RCQ.L triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
NICOX SA NICOX ORD SHS (0RCQ.L) is listed on the London Stock Exchange (LSE). Breakout Scanner monitors 0RCQ.L daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups.. Data is provided for informational purposes only and does not constitute financial advice.